Imunofan

Published · Researched 2026-09-21

Overview

Imunofan (thymohexin) is the synthetic hexapeptide Arg-α-Asp-Lys-Val-Tyr-Arg (RDKVYR), MW 836 Da, designed by chemically modifying thymopoietin's active fragment (positions 32–37). Registered in Russia (Pharmacological Committee protocol 2003; reg. ЛС-002646, 2006) as an immunoregulator with claimed antioxidant, detoxifying, hepatoprotective, and anti-multidrug-resistance effects. Sold in three dosage forms: 0.005% injection solution, 0.1 mg rectal suppositories, and dosed nasal spray (45–50 μg/dose, 40 doses). Indications per Russian labeling: oncology supportive care, opportunistic infections (CMV, herpes, toxoplasmosis, chlamydia), chronic viral hepatitis, and immune normalization after chemoradiotherapy.

Social standing

  • No social signal found. Zero mentions of "imunofan" across the full 2026 social corpus (Threads, Facebook, Instagram, Facebook Groups). The item exists in Western peptide culture only in literature (PubMed PMID 10377887; PMC review of Russian peptide drugs) and vendor/technical notes (BenchChem Dec 2025 technical overviews).
  • Retailer/educator layer: BenchChem sells research material; the official manufacturer site (imunofan.ru, НПП «Бионокс») documents the three dosage forms and clinical claims.
  • Recurring praise (where mentioned): three delivery routes (including suppositories and nasal spray); antioxidant + immune dual action; one of the few thymic peptides with real industrial production.
  • Recurring complaints/failure modes: total absence of Western community; clinical claims rest on Russian trials invisible in English; nasal-spray dose (45 μg) differs from pharmacy listings (50 μg) — minor labeling variance, UNVERIFIED which is current.
  • Representative quotes: none with attributable provenance.

Social validation

Tier 3 / UNVALIDATED — no social sources at all. Included for research completeness as a registered Russian immunomodulator with unique dosage-form range.

Key specs table

Property Value
Identity Arg-α-Asp-Lys-Val-Tyr-Arg (RDKVYR, thymohexin), thymopoietin 32–37 analog
MW 836 Da
Origin Chemically modified thymopoietin fragment (Lebedev/Pokrovskii; RF patent 2062096)
Mechanism (reported) Restores cell immunity and neutrophil bactericidal function; lowers TNF/IL-6; activates redox/antioxidant system (ceruloplasmin, lactoferrin, catalase); inhibits multidrug resistance
Forms 0.005% injectable solution; 0.1 mg rectal suppositories; nasal spray 45–50 μg/dose × 40 doses
Community-reported dosing None observed — no community protocols found

Pricing

  • Russian pharmacy: registered drug; 2026 retail RUB price UNVERIFIED.
  • US gray market / EU: research-material listings (BenchChem) — quote-on-request; no public price observed.
  • Facebook Marketplace: no used listings observed — say so plainly (none found).

What's included / what's needed

Pharma spray: 40-dose bottle + Russian insert; suppositories: blister strips; injectable: ampoules. No Western kit ecosystem.

Support reality

Distributed through Russian pharmacies (НПП «Бионокс», Moscow) with standard pharmacy support. No Western community infrastructure.

Community verdict

Imunofan is the invisible drug — a registered, industrially produced immunomodulator that the entire Western peptide conversation ignores. Its suppository form and antioxidant claims make it structurally unique, but without any community engagement it can't earn standing beyond research-completeness. Honest status: placeholder, not pick.

Regulatory & safety status

Registered drug in Russia (immunomodulator, since 2003/2006) — NOT FDA-approved, no EMA approval. Any Imunofan outside Russia/CIS is unapproved; Western listings are research chemicals not for human use. Safety signals (observed): Russian labeling claims good tolerability; no Western safety database. Never imply US/EU human-use approval.

Image view breakdown

1/8 views obtained (converted PNG→JPEG, verified 2026-09-20):

  • hero: imunofan-hero.jpg (Russian pharmacy photo — НПП «Бионокс» ИМУНОФАН nasal spray 45 μg/dose box + bottle, aptekanagagarina.ru) Missing views: side, rear, top, detail, inuse, scale, box — one real photo found.

Not medical advice. This is a research summary of publicly discussed information, not a recommendation to use any substance.

Imunofan — hero view
hero view Original vendor page URL not recorded in research dossier

Named sources

  • PMC review — The item exists in Western peptide culture only in literature (PubMed PMID 10377887; PMC review of Russian peptide drugs) and vendor/technical notes (BenchChem Dec 2025 technical overviews). (Dec 2025)

Source URLs were not recorded for these references.